AstraZeneca AB et al v. Alembic Pharmaceuticals Ltd. et al
| AstraZeneca AB and AstraZeneca Pharmaceuticals LP |
| Alembic Pharmaceuticals Ltd. and Alembic Pharmaceuticals, Inc. |
| 1:2022cv01216 |
| September 16, 2022 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 1 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on October 11, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 10 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Alembic Limited for Alembic Pharmaceuticals Ltd.; Corporate Parent Alembic Global Holding SA, for Alembic Pharmaceuticals, Inc. filed by Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc.. (Seaman, John) |
| Filing 9 ANSWER to #1 Complaint, and Defenses, by Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc..(Seaman, John) Modified on 10/11/2022 (nms). |
| Filing 8 SUMMONS Returned Executed by AstraZeneca Pharmaceuticals LP, AstraZeneca AB.Alembic Pharmaceuticals, Inc. served on 9/20/2022, answer due 10/11/2022. (Joyce, Alexandra) |
| Filing 7 DECLARATION of Service for Alembic Pharmaceuticals Ltd., by AstraZeneca AB, AstraZeneca Pharmaceuticals LP. (Attachments: #1 Exhibits A-B)(Joyce, Alexandra) Modified on 9/28/2022 (nms). |
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:22-cv-01209-RGA, 1:22-cv-01216-RGA (rjb) |
| Filing 6 Summons Issued as to Alembic Pharmaceuticals Ltd. on 9/19/2022; Alembic Pharmaceuticals, Inc. on 9/19/2022. (Attachments: #1 Summons Forms - Unsigned)(lam) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca AB, AstraZeneca Pharmaceuticals LP filed by AstraZeneca AB, AstraZeneca Pharmaceuticals LP. (lam) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,300,065. (lam) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No Earlier than August 2, 2022. Date of Expiration of Patent: 1/27/2036.Thirty Month Stay Deadline: 2/2/2025. (lam) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (lam) |
| Filing 1 COMPLAINT for Patent Infringement against Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-3961559.) - filed by AstraZeneca Pharmaceuticals LP, AstraZeneca AB. (Attachments: #1 Exhibit A, #2 Civil Cover Sheet)(lam) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
